Literature DB >> 28389856

Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain.

Juan Carlos Torre-Alonso1, Loreto Carmona2, Mireia Moreno3, Eva Galíndez4, Jesús Babío5, Pedro Zarco6, Luis Linares7, Eduardo Collantes-Estevez8, Manuel Fernández Barrial9, Juan Carlos Hermosa10, Pablo Coto11, Carmen Suárez12, Raquel Almodóvar6, Jesús Luelmo3, Santos Castañeda12, Jordi Gratacós3.   

Abstract

The objective is to establish recommendations, based on evidence and expert opinion, for the identification and management of comorbidities in patients with psoriatic arthritis (PsA). The following techniques were applied: discussion group, systematic review, and Delphi survey for agreement. A panel of professionals from four specialties defined the users, the sections of the document, possible recommendations, and what systematic reviews should be performed. A second discussion was held with the results of the systematic reviews. Recommendations were formulated in the second meeting and voted online from 1 (total disagreement) to 10 (total agreement). Agreement was considered if at least 70% voted ≥7. The level of evidence and grade of recommendation were assigned using the Oxford Centre for Evidence-Based Medicine guidance. The full document was critically appraised by the experts, and the project was supervised at all times by a methodologist. In a final step, the document was reviewed and commented by a patient and a health management specialist. Fourteen recommendations were produced, together with a checklist to facilitate the implementation. The items with the largest support from evidence were those related to cardiovascular disease and risk factors. The panel recommends paying special attention to obesity, smoking, and alcohol consumption, as they are all modifiable factors with an impact on treatment response or complications of PsA. Psychological and organizational aspects were also deemed important. We herein suggest practical recommendations for the management of comorbidities in PsA based on evidence and expert opinion.

Entities:  

Keywords:  Checklist; Comorbidity; Consensus; Guidelines; Health services research; Psoriatic arthritis

Mesh:

Year:  2017        PMID: 28389856     DOI: 10.1007/s00296-017-3702-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  78 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study.

Authors:  Agnete Malm Gulati; Anne Grete Semb; Silvia Rollefstad; Pål R Romundstad; Arthur Kavanaugh; Sasha Gulati; Glenn Haugeberg; Mari Hoff
Journal:  Ann Rheum Dis       Date:  2015-03-26       Impact factor: 19.103

3.  The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone.

Authors:  Lihi Eder; Jai Jayakar; Sutha Shanmugarajah; Arane Thavaneswaran; Daniel Pereira; Vinod Chandran; Cheryl F Rosen; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2012-06-26       Impact factor: 19.103

4.  Detecting alcoholism. The CAGE questionnaire.

Authors:  J A Ewing
Journal:  JAMA       Date:  1984-10-12       Impact factor: 56.272

5.  Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006.

Authors:  Thorvardur Jon Love; Abrar A Qureshi; Elizabeth Wood Karlson; Joel M Gelfand; Hyon K Choi
Journal:  Arch Dermatol       Date:  2010-12-20

6.  Attributable risk estimate of severe psoriasis on major cardiovascular events.

Authors:  Nehal N Mehta; YiDing Yu; Rebecca Pinnelas; Parasuram Krishnamoorthy; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  Am J Med       Date:  2011-08       Impact factor: 4.965

Review 7.  Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies.

Authors:  Luigi Naldi
Journal:  Clin Dermatol       Date:  2010 Jan-Feb       Impact factor: 3.541

8.  A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.

Authors:  Rachael L Gross; Julie S Schwartzman-Morris; Michael Krathen; George Reed; Hong Chang; Katherine C Saunders; Mark C Fisher; Jeffrey D Greenberg; Chaim Putterman; Philip J Mease; Alice B Gottlieb; Joel M Kremer; Anna Broder
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

9.  Psoriasis, psoriatic arthritis, or psoriatic disease?

Authors:  Raffaele Scarpa; Fabio Ayala; Nicola Caporaso; Ignazio Olivieri
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

10.  High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study.

Authors:  Marina N Magrey; Maria Antonelli; Neena James; Muhammad Asim Khan
Journal:  Arthritis       Date:  2013-02-14
View more
  3 in total

Review 1.  Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.

Authors:  Santos Castañeda; Carlos González-Juanatey; Miguel A González-Gay
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

2.  Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study.

Authors:  Premarani Sinnathurai; Alexandra Capon; Rachelle Buchbinder; Vibhasha Chand; Lyndall Henderson; Marissa Lassere; Lyn March
Journal:  BMC Rheumatol       Date:  2018-09-06

3.  Ankylosing spondylitis: etiology, pathogenesis, and treatments.

Authors:  Xu Cao; Xisheng Weng; Wei Zhu; Xuxia He; Kaiyuan Cheng; Linjie Zhang; Di Chen; Xiao Wang; Guixing Qiu
Journal:  Bone Res       Date:  2019-08-05       Impact factor: 13.567

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.